Pharmaceutical companies should prepare for increased scrutiny of their Asian contract manufacturers and ingredient suppliers now that US and EU authorities have reached agreement on drug GMP inspections.
In coming months, the recently signed mutual recognition agreement will allow US FDA to redirect inspectional resources from Europe to...






